Core Insights - Haofan Bio (301393.SZ) reported its Q3 2025 results, revealing that as of October 28, 2025, six institutional investors held a total of 8.0947 million shares, representing 7.50% of the company's total equity. This marks a decrease of 2.00 percentage points from the previous quarter [1] Institutional Holdings - The institutional investors include Ningbo Haoxin Enterprise Management Consulting Partnership, Suzhou Haoyin Venture Capital Partnership, Industrial and Commercial Bank of China - Huatai Securities Healthcare Mixed Fund, Suzhou Haofan Bio's repurchase special securities account, Abu Dhabi Investment Authority, and Minsheng Securities - CITIC Bank - Minsheng Securities Haofan Bio Strategic Placement No. 1 Collective Asset Management Plan [1] - The public fund that increased its holdings this period is Huatai Securities Healthcare Mixed Fund, with an increase of 0.24% [1] - A total of 75 public funds that were not disclosed in the previous quarter include various funds such as Huisheng Healthcare 6-Month Holding Mixed Fund and others [1] Social Security Fund - One social security fund, the National Social Security Fund 109 Portfolio, was not disclosed in the previous quarter [1]
机构风向标 | 昊帆生物(301393)2025年三季度已披露前十大机构持股比例合计下跌2.00个百分点